Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: marks (231), results (1000)

Dabrafenib Ver 1

Description: Chemotherapy Protocol SKIN CANCER DABRAFENIB Regimen Skin – Dabrafenib Indication Dabrafenib is recommended as an option for the first line treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinDabrafenibVer1.pdf

DH IVIg approved indications full guidance July 2011

Description: DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publication Date Target Audienc
Url: /Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

Zanubrutinib Ver1

Description: Chemotherapy Protocol LYMPHOMA ZANUBRUTINIB Regimen • Lymphoma - Zanubrutinib Indication Zanubrutinib monotherapy for the treatment of patients with previously treated Waldenstrom’s macroglobulinaemia
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Zanubrutinib.pdf

Ponatinib

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Ponatinib All licensed indications are not funded therefore an application for funding is required before prescribing
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Ponatinib.pdf

Vinorelbine Ver 1.1

Description: Chemotherapy Protocol BREAST CANCER VINORELBINE (INTRAVENOUS) Regimen Breast Cancer – Vinorelbine Indication Treatment of locally advanced or metastatic breast cancer that has
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Vinorelbine-Ver-1.1.pdf

Everolimus-Exemestane

Description: Regimen Chemotherapy Protocol BREAST CANCER EVEROLIMUS and EXEMESTANE • Breast Cancer – Everolimus-Exemestane Indication • The first or second line treatment of post
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Everolimus-Exemestane.pdf

Cetuximab (14 day)

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB (14 day) This regimen may require funding Regimen • Colorectal Cancer – Cetuximab (14 day) Indication • Metastatic colorectal
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab14day.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indication • Treatment of adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Everolimus-Lenvatinib

Description: Chemotherapy Protocol RENAL CELL EVEROLIMUS and LENVATINIB Regimen • Renal Cell – Everolimus-Lenvatinib Indication • Confirmed histological diagnosis of inoperable locally advanced or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-Lenvatinib.pdf

Lenalidomide-RituximabIV/SC

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE-RITUXIMAB (IV/SC) There are multiple versions of this protocol in use. Please ensure you have the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-RituximabIVSC.pdf

151 to 160 of 548

Previous … 14 15 16 17 18 … Next